Tibotec
Therapeutics announced it has expanded access to TMC114, an
experimental anti-HIV drug. The program will provide a
treatment option for HIV-positive patients in need of
the drug, the company said. TMC114 is an experimental
protease inhibitor that has shown some success in
early tests of treating strains of the virus that
are resistant to other protease drugs. For more
information about TMC114 or the expanded access
program visit www.tibotec.com. (AP, with additional
reporting by Advocate.com)
Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes